Prevention of atherosclerosis and of coronary heart disease

Gilbert Gosselin , M.D.

Interested in the modification of the risk factors and by pharmaceutical prevention.

Implicated in major secondary prevention trials (HOPE, PEACE, HOPE-TOO, ONTARGET, ORIGIN) and in the medical treatment of stable angina pectoris with the COURAGE trial.

Heart Outcomes Prevention Evaluation Study Investigators : Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145-53, 2000.

Tardif JC, Côté G, Lespérance J, Gosselin G, Joyal M, deGuise P, Bilodeau L, Doucet S, Harel F, Couturier A, Gallo R, Grégoire J, MultiVitamins and Probucol Study Group: Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial. Can J Cardiol (1):49-55, 2001.